These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10837182)

  • 21. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
    Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G
    J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
    J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
    Imhof A; Walter RB; Schaffner A
    Clin Infect Dis; 2003 Apr; 36(8):943-51. PubMed ID: 12684904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).
    Cybulska B; Kupczyk K; Szlinder-Richert J; Borowski E
    Acta Biochim Pol; 2002; 49(1):67-75. PubMed ID: 12136958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
    Shah T; Lai WK; Gow P; Leeming J; Mutimer D
    Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of two amphotericin B formulations against Malassezia furfur strains recovered from patients with bloodstream infections.
    Iatta R; Immediato D; Montagna MT; Otranto D; Cafarchia C
    Med Mycol; 2015 Apr; 53(3):269-74. PubMed ID: 25631480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.
    Cornely OA; Sidhu M; Odeyemi I; van Engen AK; van der Waal JM; Schoeman O
    Curr Med Res Opin; 2008 Jun; 24(6):1743-53. PubMed ID: 18477422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
    Petrikkos GL
    Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.
    Juliano RL; Grant CW; Barber KR; Kalp MA
    Mol Pharmacol; 1987 Jan; 31(1):1-11. PubMed ID: 3807887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
    López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antileishmanial activity of nano-amphotericin B deoxycholate.
    Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
    J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
    Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
    J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
    Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
    Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
    Amaral AC; Bocca AL; Ribeiro AM; Nunes J; Peixoto DL; Simioni AR; Primo FL; Lacava ZG; Bentes R; Titze-de-Almeida R; Tedesco AC; Morais PC; Felipe MS
    J Antimicrob Chemother; 2009 Mar; 63(3):526-33. PubMed ID: 19151037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
    Matsui S; Imai S; Yabuki M; Komuro S
    Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
    Khan MA; Nasti TH; Owais M
    J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.
    Ralph ED; Khazindar AM; Barber KR; Grant CW
    Antimicrob Agents Chemother; 1991 Jan; 35(1):188-91. PubMed ID: 2014976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data.
    Muñoz P; Guinea J; Narbona MT; Bouza E
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S125-31. PubMed ID: 19013336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.